Physiol. Genomics Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Physiol. Genomics 17: 140-149, 2004. First published January 27, 2004; doi:10.1152/physiolgenomics.00158.2003
1094-8341/04 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
17/2/140    most recent
00158.2003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (34)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Griffin, J. L.
Right arrow Articles by Scott, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Griffin, J. L.
Right arrow Articles by Scott, J.
Received 23 September 2003; accepted in final form 12 January 2004.
Physiological Genomics 17:140-149 (2004)
1094-8341/04 $5.00 © 2004 American Physiological Society

An integrated reverse functional genomic and metabolic approach to understanding orotic acid-induced fatty liver

Julian L. Griffin1, Stephanie A. Bonney2, Chris Mann2, Abdul M. Hebbachi3, Geoff F. Gibbons3, Jeremy K. Nicholson4, Carol C. Shoulders2 and James Scott5

1 Department of Biochemistry, University of Cambridge, Cambridge CB2 1QW, United Kingdom
2 MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London W12 ONN, United Kingdom
3 Metabolic Research Laboratory, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Headington, Oxford OX3 9JL, United Kingdom
4 Biomedical Sciences, Faculty of Medicine, Imperial College London, Exhibition Road, South Kensington, London, United Kingdom
5 Genetics and Genomics Research Institute, Faculty of Medicine, Imperial College London, South Kensington, Armstrong Road, London SW7 2AZ, United Kingdom

In functional genomics, DNA microarrays for gene expression profiling are increasingly being used to provide insights into biological function or pathology. To better understand the significance of the multiple transcriptional changes across a time period, the temporal changes in phenotype must be described. Orotic acid-induced fatty liver disease was investigated at the transcriptional and metabolic levels using microarrays and metabolic profiling in two strains of rats. High-resolution 1H-NMR spectroscopic analysis of liver tissue indicated that Kyoto rats compared with Wistar rats are predisposed to the insult. Metabolite analysis and gene expression profiling following orotic acid treatment identified perturbed metabolic pathways, including those involved in fatty acid, triglyceride, and phospholipid synthesis, ß-oxidation, altered nucleotide, methyl donor, and carbohydrate metabolism, and stress responses. Multivariate analysis and statistical bootstrapping were used to investigate co-responses with transcripts involved in metabolism and stress responses. This reverse functional genomic strategy highlighted the relationship between changes in the transcription of stearoyl-CoA desaturase 1 and those of other lipid-related transcripts with changes in NMR-derived lipid profiles. The results suggest that the integration of 1H-NMR and gene expression data sets represents a robust method for identifying a focused line of research in a complex system.

transcriptomics; metabolomics/metabonomics; DNA microarray; system biology; bioinformatics




This article has been cited by other articles:


Home page
Physiol. GenomicsHome page
J. L. Griffin and A. Vidal-Puig
Current challenges in metabolomics for diabetes research: a vital functional genomic tool or just a ploy for gaining funding?
Physiol Genomics, June 1, 2008; 34(1): 1 - 5.
[Abstract] [Full Text] [PDF]


Home page
Physiol. GenomicsHome page
M. Liang and B. Ventura
Physiological genomics in PG and beyond: October to December 2005
Physiol Genomics, December 14, 2005; 24(1): 1 - 3.
[Full Text] [PDF]


Home page
FASEB J.Home page
D. M. Mutch, W. Wahli, and G. Williamson
Nutrigenomics and nutrigenetics: the emerging faces of nutrition
FASEB J, October 1, 2005; 19(12): 1602 - 1616.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
C. J. Lelliott, M. Lopez, R. K. Curtis, N. Parker, M. Laudes, G. Yeo, M. Jimenez-Linan, J. Grosse, A. K. Saha, D. Wiggins, et al.
Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis
FASEB J, July 1, 2005; 19(9): 1108 - 1119.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2004 by the American Physiological Society.